To the full analysis
Buyback calculator for Gyre Therapeutics
Gyre Therapeutics stock: key metrics
GYREGyre Therapeutics had an operating margin of 9.9% and a return on invested capital (ROIC) of 9.6% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 98.3% | −1.5% | 7.6% |
| 2007 | 93.8% | −274.5% | −242.5% |
| 2008 | 96.3% | −140.1% | −127.8% |
| 2009 | 97.2% | −160.9% | −157.2% |
| 2010 | 97.7% | 15.3% | 12.7% |
| 2011 | 97.5% | −10.0% | −8.7% |
| 2012 | 100.0% | −8.4% | −12.1% |
| 2013 | −80.7% | −1,301.1% | −1,287.0% |
| 2014 | −190.5% | −414.2% | −1,799.4% |
| 2015 | −240.5% | −788.7% | −843.5% |
| 2016 | −2,545.4% | −5,117.3% | −4,246.9% |
| 2017 | 83.0% | −2,143.6% | −2,118.0% |
| 2018 | −2,383.3% | −563,700.0% | −500,916.7% |
| 2019 | no data | no data | no data |
| 2020 | 56.3% | −273.9% | −265.1% |
| 2021 | −4.5% | −1,141.0% | −1,198.3% |
| 2022 | 95.3% | 9.0% | 2.3% |
| 2023 | 95.9% | −59.3% | −81.9% |
| 2024 | 96.3% | 15.3% | 11.4% |
| 2025 | 95.4% | 9.9% | 4.3% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 3.2% | −3.3% | 2.6% |
| 2007 | −54.4% | −31.8% | −28.4% |
| 2008 | −44.7% | −26.0% | −26.0% |
| 2009 | −57.1% | −20.8% | −12.3% |
| 2010 | 11.9% | 5.1% | 4.1% |
| 2011 | −4.9% | −4.4% | −3.3% |
| 2012 | −4.0% | −2.1% | −3.7% |
| 2013 | −34.7% | −77.4% | −32.0% |
| 2014 | −29.9% | −26.3% | −29.1% |
| 2015 | −47.0% | −63.4% | −21.2% |
| 2016 | −100.0% | −63.2% | −44.5% |
| 2017 | −70.1% | −48.3% | −54.6% |
| 2018 | −25.1% | −34.3% | −24.1% |
| 2019 | −80.7% | −47.6% | −56.0% |
| 2020 | −73.0% | −61.3% | −58.6% |
| 2021 | −100.0% | no data | −100.0% |
| 2022 | 5.4% | 20.8% | 2.7% |
| 2023 | 200.0% | −62.9% | −79.7% |
| 2024 | 19.1% | 46.2% | 9.6% |
| 2025 | 4.7% | 9.6% | 3.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 9 May 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.